Wirth S, et al. - In this multicenter, randomized, double-blind, controlled study, the researchers assessed primarily the safety and also the efficacy of moxifloxacin (MXF) in children with complicated intra-abdominal infections (cIAIs). For this investigation, 451 pediatric subjects aged 3 months to 17 years with cIAIs were treated with intravenous/oral MXF (N = 301) or comparator (COMP, intravenous ertapenem followed by oral amoxicillin/clavulanate; N = 150) for 5 to 14 days. In children with cIAIs, MXF treatment was well tolerated. Compared with COMP, a lower clinical cure rate was observed with MXF treatment. A recommendation of MXF for children with cIAIs was not supported when alternative more efficacious antibiotics with better safety profile were available.